Taken together, IL‐1β plays a central role in the attenuation of ICB via orchestrating immune hyporesponsiveness, which is similar to the notion that sustained IFN signaling induces tumor resistance to ICB,60 suggesting a strong rationale to combine ICB with IL‐1β blockade. Here, IL1B is linked to neoplasm.